Amgen Report on Nuzzel

endpts.com - John Carroll - - Merck, Amgen back a $30M play for Ribometrix - one of the upstarts making its mark in drugging RNA

Merck, Amgen back a $30M play for Ribometrix - one of the upstarts making its mark in drugging RNA

Endpoints News – John Carroll -
reuters.com - Reuters Editorial - Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Reuters – Reuters Editorial
jdsupra.com - Coherus Files Responsive Appellate Brief in Amgen v. Coherus (pegfilgrastim)

Coherus Files Responsive Appellate Brief in Amgen v. Coherus (pegfilgrastim)

JD Supra
columbia.edu - AMGEN - Grant Renewal

AMGEN - Grant Renewal

Columbia University Press
reuters.com - Reuters Editorial - Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Reuters – Reuters Editorial
einnews.com - Better Buy: Amgen Inc. vs. Pfizer Inc. - World News Report

Better Buy: Amgen Inc. vs. Pfizer Inc. - World News Report

EIN News
nih.gov - NIH, Amgen Foundation, and FNIH renew support for undergraduate research opportunities

NIH, Amgen Foundation, and FNIH renew support for undergraduate research opportunities

National Institutes of Health (NIH)
reuters.com - Reuters Editorial - Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Reuters – Reuters Editorial
aktiencheck.de - aktiencheck.de AG - Amgen: Der Hammer! ()

Amgen: Der Hammer! ()

aktiencheck.de – aktiencheck.de AG

Top Sources reporting on Amgen

Name
1 com
2 Endpoints News
3 EIN News
4 Reuters
5 aktiencheck.de
6 Seeking Alpha
7 Bloomberg.com